Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Child , Cholestyramine Resin/therapeutic use , Colestipol/therapeutic use , Diet, Fat-Restricted , Hyperlipidemias , Feeding Behavior , Hyperlipidemias/classification , Hyperlipidemias/diet therapy , Hyperlipidemias/drug therapy , Hyperlipidemias/metabolismABSTRACT
The purpose of this investigation was to determine whether the oral administration of colestipol would increase the systemic elimination of indomethacin following intravenous administration [2mg/kg] to rabbits. Adsorption studies in-vitro were also performed. The in-vivo results indicate that colestipol do not affect the serum levels of indomethacin. The values during colestipol treatment colestipol do not affect the serum levels of indomethanic. The values during colestipol treatment were lower than those for the control, but the differences in concentrations were not significant. No significant differences were observed in any of the calculated pharmacokinetic parameters between the control and colestipol treated rabbits. This in-vitro adsorption studies supported the in-vivo results. colestipol was found to have a poor adsorption capacity for indomethacin. The Freundlich constant [K] for adsorption was 0.9mg/g at equilibrium [3h]. Furthermore, three successive washings of the drug- adsorbent mixture, with 20 mL buffer solution, resulted in 33.8% desorption. Based on the in-vivo andin-vitro studies it is not likely that the administration of colestipol will result in a change in the pharmacokinetic parameters of indomethanin in man
Subject(s)
Animals, Laboratory , Colestipol , Colestipol/pharmacokinetics , Rabbits/drug effectsABSTRACT
Las dislipoproteinemias son condiciones de diversa etiología y pueden ser secundarias a alguna enfermedad o trastornos primarios del metabolismo de las lipoproteínas. El tratamiento de las dislipoproteinemias se basa en identificar la causa y establecer un tratamiento específico. El tratamiento nutricional constituye un elemento fundamental en el manejo de estas enfermedades y debe de ser permanente. La intervención farmacológica se introduce cuando no se logra normalizar el perfil de lípidos y lipoproteínas, a pesar de que el paciente mantenga un buen control dietético. Este informe presenta los criterios para iniciar la terapía hipolipemiante; se discuten las indicaciones, efectos secundarios y dosificación de los principales agentes hipollipemiantes de uso actual.